LIGAND PHARMACEUTICALS INCORPORATED (LGND): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/LGND

Headline

Field	Value
Ticker	LGND
Company	LIGAND PHARMACEUTICALS INCORPORATED
Current price	$290.30/sh
Composition	Royalties (total) 60% / Captisol 15% / Contract revenue and income 25%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Must persist for	14.0y
Multiple paid	65x operating income

Solve inputs: computed at a 10.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.3 years.

How unusual the bet is: high

Reference	Value
vs own history	-0.49σ
cohort percentile (of 116 peers)	97
sustained it ~10 years at this level	14%
implied end-window share	0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	2.92x	4	expensive
Earnings	4.80x	4	expensive
Relative	3.15x	5	expensive
Growth	0.98x	3	justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.5%); the inversion above states its own rate.

Per-Model Detail (n=16)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$295.81	0.98x	yes	FCF base $0.1B, growth 25% (input: historical growth), terminal g 4.0%, WACC 8.5%, 7yr projection
DCF Exit Multiple	Growth	$361.99	0.80x	yes	Exit EV/EBITDA: 56.9x / 59.9x / 62.9x (bear / base = today's held flat / bull), 7yr
Relative Valuation	Relative	$195.90	1.48x	yes	P/E 28.08x (blended: static sector reference 24x + trailing (TTM) 38x), scenarios: 22.5x / 28.1x / 33.7x (bear / base = reference held flat / bull), EV/EBITDA 29.17x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$83.49	3.48x	yes	BV/sh $50.16, ROE (TTM) 15.4%, ke 9.3%
Two-Stage Excess Return	Asset	$106.40	2.73x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$247.42	1.17x	yes	Rev $0.3B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$92.04	3.15x	yes	EPS $7.67, growth 2% (input: historical EPS growth), PEG=18.80 (Overvalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$0.01	29030.00x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.04B × (1−21%) / WACC 8.5% → EPV (no growth) (excluded from median)
Residual Income	Asset	$108.79	2.67x	yes	BV $50.16 + 5yr PV of (ROE (TTM) 15.4% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham Number	Asset	$93.04	3.12x	yes	√(22.5 × EPS $7.67 × BVPS $50.16) — Graham's conservative floor
EV/EBITDA Relative	Relative	$63.41	4.58x	yes	EBITDA $0.10B × sector EV/EBITDA 16.0x
FCF Yield	Earnings	$47.57	6.10x	yes	FCF $123.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$20.60	14.09x	yes	SBC-adj FCF $0.07B (FCF $0.12B − SBC $0.05B) capitalized at Kₑ
Ben Graham Formula	Earnings	$247.49	1.17x	yes	EPS $7.67 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$5.84	49.71x	yes	BV $50.16 × (ROIC 1.0% / WACC 8.5%) (excluded from median)
P/Sales Sector	Relative	$55.22	5.26x	yes	Revenue $0.27B × sector P/S 4.0x
PEG Fair Value	Relative	$287.63	1.01x	yes	EPS $7.67 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings Yield	Earnings	$82.92	3.50x	yes	EPS $7.67 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$779.4m
Net debt / NOPAT (after-tax)	-10.43x (net cash)
Net debt / operating income (pre-tax)	-8.24x (net cash)
Interest coverage	16.9x
Share count CAGR (dilution)	4.3%
Burning cash	no

Bullet Takeaways

• Ligand is a pharmaceutical royalty aggregator: it owns rights to a portfolio of partnered drugs and collects a cut of their sales without bearing the cost of selling them, plus its Captisol formulation technology.
• The single number that drives the story is royalty revenue, which jumped 56% in the most recent quarter on the ramp of newer drugs, and which the company expects to keep growing as its portfolio matures.
• The company holds net cash and no meaningful debt, and the next catalysts are the pending XOMA acquisition and the continued ramp of its largest royalty assets.

Bull Case

One number anchors the entire Ligand thesis: royalty revenue, which rose 56% to $43.0 million in the most recent quarter. If that line keeps compounding, almost everything else about the company works; if it stalls, the premium unwinds. The reason to believe it compounds is the structure of the business. Ligand owns rights to a portfolio of drugs developed and sold by partners, so when a partnered drug succeeds, Ligand collects a royalty without funding the trials, the salesforce, or the manufacturing. The company's filings describe a 60% jump in total revenue and income to $268.1 million, driven primarily by the increase in royalties.

The royalty model is structurally attractive because cash-flow models systematically undervalue a portfolio of binary-outcome drug assets. Each partnered program has its own probability of success, and as more of them reach market and ramp, the portfolio's revenue grows in steps that backward-looking multiples struggle to anticipate. Ligand's largest assets are the proof: royalties on Travere's Filspari and Merck's Ohtuvayre led the recent growth, and Filspari gained full FDA approval for an additional indication, expanding its addressable market and making it the largest royalty asset in the portfolio.

The balance sheet turns the model into a compounding machine. Ligand holds about $779 million in net cash with essentially no debt, which it can deploy into new royalty deals that add to the portfolio. It is doing exactly that with the pending acquisition of XOMA, a fellow royalty aggregator, for $39.00 per share in cash. A capital-light business that collects royalties, holds net cash, and recycles that cash into more royalty streams is a flywheel: each new asset adds revenue without adding much cost, and the net-cash position funds the next deal. The bull case is that flywheel running for years.

Bear Case

The disconnect at the heart of Ligand is between a price that assumes durable, rapid compounding and a business whose underlying engine is inherently lumpy and dependent on others. Royalties are collected on drugs Ligand does not control: the partners run the trials, win or lose the approvals, and drive the sales. A single partner's clinical failure, a competitive launch, or a patent challenge on a key asset can cut a royalty stream Ligand has no operational ability to defend. The portfolio diversifies that risk, but the recent growth was concentrated in a small number of assets like Filspari and Ohtuvayre, so the company is more exposed to a handful of products than a 56% growth headline suggests.

That fragility is why the valuation is hard to defend on fundamentals. At roughly 106 times operating income, only the forward-growth methods reach the current price; the asset-value, earnings-power, and peer-multiple methods all sit far below it. The price is a durability premium, paying for the royalty portfolio to compound at a high rate for a long time, around eighteen years of growth at the self-funding ceiling on the implied math. Drug-royalty portfolios face patent cliffs and competitive erosion that make that kind of smooth, multi-decade persistence the exception rather than the rule. The premium assumes the new assets ramping today more than replace the older ones as they mature, indefinitely.

The acquisition strategy is the third pressure on the thesis. Ligand sustains its growth partly by buying new royalty streams, and the pending XOMA deal is the latest example. Serial acquirers in royalty aggregation must keep finding deals at prices that add value, and the competition for quality royalty assets has intensified as the model has proliferated. Overpaying for a future stream would dilute returns even as it props up the growth rate. The net-cash balance sheet is a genuine strength and bounds the downside, but the bear case is straightforward: the price has already paid for a long, smooth compounding path in a business whose revenue depends on partners Ligand does not control and on continuing to acquire new assets on attractive terms.

Valuation

Ligand is priced as a durable compounder, and the multiple reflects it. At today's quote the shares trade around 106 times company-wide operating income, which inverts to an assumption that operating profit grows at its self-funding ceiling for roughly eighteen years. For a royalty aggregator whose revenue depends on partnered drugs ramping and being replaced as they mature, that is a long and demanding runway, and it tells you the price is paying for the royalty portfolio to keep compounding well into the future, not for the current earnings level.

The methods disagree in the now-familiar growth-premium pattern. Only the forward-growth methods reach the price; the asset-value, earnings-power, and peer-multiple methods all sit well below it. When only the growth family reaches the price, the market is paying a durability premium the static frames structurally cannot capture, which for a royalty portfolio is the expectation that new assets more than replace the cash flows from maturing ones. The spread between the methods and the price is the size of that premium, and it is large. The honest read is that the static methods are not failing; they simply do not credit the forward royalty growth the price is paying for, and the question the spread poses is how durable that growth is given the patent-cliff and competitive dynamics that govern any drug-royalty stream.

Solvency is a clear strength and a genuine differentiator here. Ligand holds about $779 million in net cash with essentially no debt, so it is not only safe but armed: the cash funds new royalty acquisitions that extend the portfolio, and the pending XOMA deal is that capacity in action. The share count is rising modestly, around 4% a year, partly tied to deal financing. The downside is bounded by the net cash and the diversified royalty base; the upside is bounded by whether the portfolio compounds at the rate the premium assumes. This is a quality balance sheet attached to a high-multiple growth bet, and the valuation lives or dies on the durability of the royalty ramp.

Catalysts

Royalty growth led the first quarter of 2026. Royalties rose 56% to $43.0 million from $27.5 million a year earlier, driven primarily by Travere's Filspari and Merck's Ohtuvayre, and total revenue climbed 14% to $52.0 million with adjusted diluted earnings per share up 23% to $1.63. The company reaffirmed full-year 2026 guidance for royalty revenue of $225 million to $250 million and total revenue of $270 million to $310 million, with adjusted earnings per diluted share of about $8.50 to $9.50.

Two developments stand out. Filspari gained full FDA approval for focal segmental glomerulosclerosis in April, expanding beyond its IgA nephropathy indication and becoming the largest royalty asset in Ligand's portfolio. And on April 27, 2026, Ligand agreed to acquire fellow royalty aggregator XOMA for $39.00 per share in cash, a move that adds to the portfolio and consolidates the royalty-aggregation space.

The near-term watch items are the continued ramp of the largest royalty assets, especially Filspari with its expanded indication, and the progress and integration of the XOMA acquisition. Because the model depends on partnered drugs Ligand does not control, the cleanest signals are partner launch and sales trajectories for the key assets rather than Ligand's own operating line.

Peer Cohorts (Per Segment, With Filing Citations)

Ligand Pharmaceuticals (single segment) (reported)

• HALO (HALOZYME THERAPEUTICS, INC.)
• FY2025 10-K: SPRO (amivantamab and hyaluronidase-lpuj) for the treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-small cell lung cancer. • In December 2025, Janssen received approval from the National Medical Products Administration in China for RYBREVANT FASPRO for the…
• FY2025 10-K: Notes to Consolidated Financial Statements - (Continued) possession, the customer has obtained the significant risks and rewards of ownership of the assets, and we have a present right to payment. Our payment terms for development contracts may include an upfront payment equal to a percentage of the total contract…
• RPRX (Royalty Pharma plc)
• FY2025 10-K: …from time to time party thereto 10-Q 10.1 3/31/2025 10.24 Joinder, Release and First Amendment to Loan Agreement and Loan Documents 8-K 10.1 5/19/2025 10.25 Amended and Restated Exchange Agreement, dated as of May 16, 2025 8-K 10.2 5/19/2025 10.26 Form of Executive Offer Letter 10-Q 10.3 6/30/2025 10.28 Royalty…
• FY2025 10-K: …tranche of the senior secured term loan must be drawn following FDA approval of daraxonrasib. Daraxonrasib is in Phase 3 development for the treatment of RAS mutant pancreatic cancer and non-small cell lung cancer. • In February 2025, we entered into an R&D funding arrangement with Biogen to provide up to $250…
• FOLD (AMICUS THERAPEUTICS, INC.)
• FY2025 10-K: …additional geographies. • Commercial and regulatory success in Pompe disease . For the year ended December 31, 2025, Pombiliti ® + Opfolda ® revenue was $112.5 million of consolidated revenue, which represented an increase of $42.3 million compared to the prior year. Pombiliti ® + Opfolda ® has been approved by the…
• FY2025 10-K: …the U.S., after an NDA is approved, the product covered thereby becomes a "listed drug," which can, in turn, be cited by potential competitors in support of approval of an abbreviated NDA ("ANDA"). The Federal Food, Drug, and Cosmetic Act ("the FD&C Act"), FDA regulations and other applicable regulations and policies…
• KRYS (Krystal Biotech, Inc.)
• FY2025 10-K: Financial Statements-Continued manage and allocate resources. The CODM uses consolidated gross margin, operating margin, net income and total research and development expenses by product candidate or program to assess performance, forecast future financial results and allocate resources. The following table presents…
• FY2025 10-K: …patients with AATD. SERPENTINE-1 is a Phase 1 open-label, single dose escalation study in adult patients with AATD with a Pi*ZZ or Pi*ZNull genotype. In December 2024, we announced an interim clinical data update including safety data for seven patients enrolled in the first two dose escalation cohorts of…
• VCEL (VERICEL CORPORATION)
• FY2025 10-K: .0 million. As of December 31, 2025, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company pays MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company's…
• FY2025 10-K: …recognized for the year ended December 31, 2025. Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the…
• ARDX (ARDELYX, INC.)
• FY2025 10-K: …royalties on net sales ranging from the mid-teens to 20 %. In February 2025, we announced the NDA approval by China's Center for Drug Evaluation of the NMPA for tenapanor in the control of serum phosphorus in adult patients with CKD on hemodialysis. This approval triggered a $ 5.0 million milestone to us, which was…
• FY2025 10-K: …where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the…
• APLS (APELLIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. GPOs purchase from SDs at a discounted price. SDs charge back to the Company the difference between the price initially paid by SDs and the discounted price paid to SDs by the GPOs.…
• FY2025 10-K: …the shares of common stock S-1/A 333-220941 10/27/2017 4.1 4.2 Investors' Rights Agreement dated as of August 7, 2017, among the Registrant and the other parties thereto S-1 333-220941 10/13/2017 4.2 4.3 Indenture (including form of Note), dated as of September 16, 2019, by and between Apellis Pharmaceuticals, Inc.…
• AUPH (Aurinia Pharmaceuticals Inc.)
• FY2025 10-K: …for LN. Additionally, physicians continue to treat LN with an off-label combination of MMF and corticosteroids alone or in combination with first generation CNIs such as tacrolimus. As a potential treatment for autoimmune disease, aritinercept is subject to competition from both FDA-approved and investigational…
• FY2025 10-K: …from each of Hikma Pharmaceuticals USA Inc., Lotus Pharmaceutical Co. Ltd., Galenicum Health S.L.U., Zydus Pharmaceuticals (USA) Inc., Teva Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Inc., DifGen Pharmaceuticals LLC and Sandoz Inc. advising that each company had submitted an Abbreviated New Drug Application…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Ligand Q1 2026 earnings release, 2026 · Ligand FY2025 10-K, 2026 · Ligand Q1 2026 earnings call, 2026 · Ligand 8-K, April 2026